Is Abbott Laboratories a Buy on the Dip?


Shares of top healthcare stock Abbott Laboratories (NYSE:ABT) are down 8% over the past month while the S&P 500 has been relatively steady, up by less than 1% during that period. That’s because the company recently lowered its guidance for the year, which led to investors selling off the stock in early June.

However, the business still has strong fundamentals and pays a decent dividend. Should investors considering adding Abbott’s stock to their portfolios now that it is trading at a lower price, or is it likely headed for more of a decline? Let’s take a look at its updated valuation and determine whether it is still a good buy today.

A group of scientists looking at a report.

Image source: Getty Images.

Why did Abbott reduce its earnings forecast?

On June 1, the healthcare company announced it was updating its projections for the current year as it was seeing a steep decline in demand for COVID-19 testing. A big part of the reason is that more than half of Americans have received at least one dose of a vaccine thus far, and in 12 states the percentage is as high as 70%. With fewer concerns surrounding COVID-19, it’s not surprising to see the demand for testing hasn’t been as strong. Abbott anticipates this trend will continue throughout the year.

READ:  Where Will fuboTV Be in 5 Years?

The company’s CEO Robert B. Ford notes that business outside of COVID-19 “is accelerating.” However, that wasn’t enough for Abbott to avoid lowering its diluted earnings per share (EPS) forecast to a range between $2.75 and $2.95 — previously it was expecting that number to be $3.74 or better. 

What does this do to its valuation?

With a reduction in earnings, investors adjust how much they are willing to pay for the stock, which is why shares of Abbott tanked on the news. The stock fell to $105.79 on June 1 (down 9.3%). The last time it closed lower than that was on Oct. 30, 2020 when it finished trading at $105.11. Today, with its share price around $109, Abbott’s stock is trading at a future price-to-earnings (P/E) ratio of 38 with the updated guidance. Under the previous forecast, that multiple would be just 29.

Even the lower multiple would still look steep compared to some other top healthcare stocks.

LLY PE Ratio (Forward) Chart

LLY PE Ratio (Forward) data by YCharts

Typically, for healthcare stocks to trade at hefty earnings multiples (in the neighborhood of 30 or better), investors expect them to generate strong growth numbers. And while Abbott has been performing well, if you take out the impact of COVID-19 testing, they aren’t all that amazing. In its first-quarter results for the period ending March 31, outside of its diagnostics business (which grew at a rate of 120%), the only segment that generated more than 10% sales growth was medical devices (13%). Its nutrition and pharmaceutical-related sales were up by just 6.9% and 2.5%, respectively.

READ:  A Project Manager's Guide to PERT Charts (2021)

Should you buy shares of Abbott today?

Abbott is a good long-term investment to hang on to. It yields 1.49%, which is better than the S&P 500 average of less than 1.4%. And the business is still performing well. Even at the low end of its earnings forecast, EPS of $2.75 is still better than what it posted in 2020 — 2.50.

But investors are right to be worried about what a full year might look like without COVID-19 testing giving Abbott’s numbers a boost. And with the stock trading at such a high multiple of earnings, I wouldn’t be surprised to see Abbott’s stock fall further down as the year goes on and investors shift to stocks that will benefit as a result of the economy opening back up. Although it remains a good long-term buy, there are better options out there for investors which have much better growth prospects than Abbott. But if you are inclined to buy the stock, it may be a good option to simply wait for more of a drop in price.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

READ:  Pipedrive CRM Review 2021: Features, Pricing & More




View more information: https://www.fool.com/investing/2021/06/09/is-abbott-laboratories-a-buy-on-the-dip/

Articles in category: investing

Leave a Reply

Back to top button